RA'ANANA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that the Japan Patent Office has granted Patent No. 7777598. This patent covers the Company's novel Convertible Dual Lumen Cannula device and method of use, securing exclusive rights in one of the world's most advanced medical device markets.The patent grants Inspira exc ...

Core Insights - Inspira Technologies has been granted Patent No. 7777598 by the Japan Patent Office for its Convertible Dual Lumen Cannula device, securing exclusive rights in Japan until 2041, complementing its existing U.S. patent [1][2] - The patented technology allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly after insertion, potentially reducing infection risks and procedural complications compared to traditional solutions [3][4] - The company aims to commercialize the cannula as a high-value disposable product, enhancing patient safety and procedural efficiency while addressing the high manufacturing costs of traditional dual lumen cannulas [4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its INSPIRA™ ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The company is developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake, and advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [5] - With a growing IP portfolio and strategic operational streamlining, Inspira Technologies is positioned as an attractive player in the life-support and MedTech landscape, aligning with industry trends such as consolidation and potential strategic partnerships [5]